EfavirenzThird Party Manufacturing in India

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that specifically targets the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1). Unlike nucleoside reverse transcriptase inhibitors that compete at the active site, efavirenz binds directly to a non-catalytic allosteric site on HIV-1 reverse transcriptase, inducing a conformational change that disrupts the enzyme's catalytic activity. This binding inhibits both the RNA-dependent and DNA-dependent DNA polymerase activities of the enzyme, effectively blocking the transcription of viral RNA into DNA — an essential step in the HIV replication cycle. By preventing the generation of DNA copies of viral RNA, efavirenz halts the synthesis of new virions and reduces the viral load in infected individuals. Efavirenz is highly selective for HIV-1 reverse transcriptase and does not inhibit HIV-2 reverse transcriptase or human cellular DNA polymerases alpha, beta, gamma, or delta, contributing to its specificity. As a first-generation NNRTI, efavirenz has a low genetic barrier to resistance, meaning a single mutation (particularly the K103N mutation in the reverse transcriptase gene) can confer high-level resistance. For this reason, efavirenz is always used as part of a combination antiretroviral regimen, typically with two nucleoside reverse transcriptase inhibitors, to achieve durable viral suppression and prevent the emergence of resistant viral strains.

Therapeutic Uses

Efavirenz is a cornerstone antiretroviral medication for the management of HIV-1 infection:

• HIV-1 Infection (First-Line Therapy): Efavirenz is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults, adolescents, and children aged 3 months and older weighing at least 3.5 kg. It has been a preferred first-line NNRTI in global HIV treatment guidelines for decades.
• HIV Pre-Exposure Prophylaxis (PrEP): When used as part of combination regimens, efavirenz contributes to the prevention of HIV transmission in high-risk populations.
• Single-Tablet Regimens: Efavirenz is a component of fixed-dose combination tablets co-formulated with tenofovir disoproxil fumarate and emtricitabine, enabling once-daily single-tablet therapy that improves treatment adherence.

The standard adult dosage is 600mg orally once daily, taken on an empty stomach to reduce central nervous system side effects. Efavirenz is also used in combination with other antiretrovirals for the prevention of mother-to-child transmission of HIV during pregnancy.

Why Manufacturers Choose Efavirenz

Efavirenz is one of the most widely prescribed antiretroviral molecules globally, particularly in developing countries where it has been a mainstay of first-line HIV therapy for over two decades. Its inclusion in the WHO Essential Medicines List and its high-volume procurement by global health organizations like UNITAID, PEPFAR, and the Global Fund create consistent, large-scale demand. Indian manufacturers with WHO-GMP certified facilities and WHO-prequalified product dossiers are the dominant global suppliers of efavirenz tablets and fixed-dose combinations. The 600mg tablet is a high-volume SKU with substantial export demand to Africa, Asia, and Latin America.

This makes Efavirenz one of the most sought-after antiretroviral molecules for third party manufacturing in India, with consistent demand from PCD franchise operators, government tenders, and export-oriented companies.